Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy
Advances in nanotechnology have brought innovations to cancer therapy. Nanoparticle-based anticancer drugs have achieved great success from bench to bedside. However, insufficient therapy efficacy due to various physiological barriers in the body remains a key challenge. To overcome these biological...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/23/7750 |
| _version_ | 1797399831199612928 |
|---|---|
| author | Lamei Guo Jinjun Yang Hao Wang Yu Yi |
| author_facet | Lamei Guo Jinjun Yang Hao Wang Yu Yi |
| author_sort | Lamei Guo |
| collection | DOAJ |
| description | Advances in nanotechnology have brought innovations to cancer therapy. Nanoparticle-based anticancer drugs have achieved great success from bench to bedside. However, insufficient therapy efficacy due to various physiological barriers in the body remains a key challenge. To overcome these biological barriers and improve the therapeutic efficacy of cancers, multistage self-assembled nanomaterials with advantages of stimuli-responsiveness, programmable delivery, and immune modulations provide great opportunities. In this review, we describe the typical biological barriers for nanomedicines, discuss the recent achievements of multistage self-assembled nanomaterials for stimuli-responsive drug delivery, highlighting the programmable delivery nanomaterials, in situ transformable self-assembled nanomaterials, and immune-reprogramming nanomaterials. Ultimately, we perspective the future opportunities and challenges of multistage self-assembled nanomaterials for cancer immunotherapy. |
| first_indexed | 2024-03-09T01:45:48Z |
| format | Article |
| id | doaj.art-413b42c6f0ae4dfda00737e4896aed39 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T01:45:48Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-413b42c6f0ae4dfda00737e4896aed392023-12-08T15:22:13ZengMDPI AGMolecules1420-30492023-11-012823775010.3390/molecules28237750Multistage Self-Assembled Nanomaterials for Cancer ImmunotherapyLamei Guo0Jinjun Yang1Hao Wang2Yu Yi3Tianjin Key Laboratory of Hazardous Waste Safety Disposal and Recycling Technology, School of Environmental Science and Safety Engineering, Tianjin University of Technology, 391 Binshui Xidao, Xiqing District, Tianjin 300384, ChinaTianjin Key Laboratory of Hazardous Waste Safety Disposal and Recycling Technology, School of Environmental Science and Safety Engineering, Tianjin University of Technology, 391 Binshui Xidao, Xiqing District, Tianjin 300384, ChinaCAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing 100190, ChinaCAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing 100190, ChinaAdvances in nanotechnology have brought innovations to cancer therapy. Nanoparticle-based anticancer drugs have achieved great success from bench to bedside. However, insufficient therapy efficacy due to various physiological barriers in the body remains a key challenge. To overcome these biological barriers and improve the therapeutic efficacy of cancers, multistage self-assembled nanomaterials with advantages of stimuli-responsiveness, programmable delivery, and immune modulations provide great opportunities. In this review, we describe the typical biological barriers for nanomedicines, discuss the recent achievements of multistage self-assembled nanomaterials for stimuli-responsive drug delivery, highlighting the programmable delivery nanomaterials, in situ transformable self-assembled nanomaterials, and immune-reprogramming nanomaterials. Ultimately, we perspective the future opportunities and challenges of multistage self-assembled nanomaterials for cancer immunotherapy.https://www.mdpi.com/1420-3049/28/23/7750cancer immunotherapyin vivo self-assemblydrug deliverymultistagestimuli–responsetumor microenvironment |
| spellingShingle | Lamei Guo Jinjun Yang Hao Wang Yu Yi Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy Molecules cancer immunotherapy in vivo self-assembly drug delivery multistage stimuli–response tumor microenvironment |
| title | Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy |
| title_full | Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy |
| title_fullStr | Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy |
| title_full_unstemmed | Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy |
| title_short | Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy |
| title_sort | multistage self assembled nanomaterials for cancer immunotherapy |
| topic | cancer immunotherapy in vivo self-assembly drug delivery multistage stimuli–response tumor microenvironment |
| url | https://www.mdpi.com/1420-3049/28/23/7750 |
| work_keys_str_mv | AT lameiguo multistageselfassemblednanomaterialsforcancerimmunotherapy AT jinjunyang multistageselfassemblednanomaterialsforcancerimmunotherapy AT haowang multistageselfassemblednanomaterialsforcancerimmunotherapy AT yuyi multistageselfassemblednanomaterialsforcancerimmunotherapy |